Clinton Yam

1.5k total citations
45 papers, 711 citations indexed

About

Clinton Yam is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Clinton Yam has authored 45 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 22 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Clinton Yam's work include Breast Cancer Treatment Studies (14 papers), Advanced Breast Cancer Therapies (11 papers) and Cancer Genomics and Diagnostics (11 papers). Clinton Yam is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Advanced Breast Cancer Therapies (11 papers) and Cancer Genomics and Diagnostics (11 papers). Clinton Yam collaborates with scholars based in United States, Singapore and Japan. Clinton Yam's co-authors include Stacy L. Moulder, Sendurai A. Mani, Huaiyu Ma, Robert M. Hoffman, Michele McElroy, Hiroyuki Kishimoto, Michael Bouvet, Ming Zhao, Katsuhiro Hayashi and Mien‐Chie Hung and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Clinton Yam

39 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clinton Yam United States 17 357 231 132 124 119 45 711
Yunxin Lai China 9 504 1.4× 227 1.0× 86 0.7× 175 1.4× 61 0.5× 10 779
Joris van de Haar Netherlands 8 326 0.9× 239 1.0× 191 1.4× 74 0.6× 54 0.5× 16 602
Matthew A. Spear United States 18 459 1.3× 629 2.7× 89 0.7× 73 0.6× 98 0.8× 59 1.2k
Shuguang Zuo China 18 274 0.8× 393 1.7× 224 1.7× 38 0.3× 52 0.4× 26 794
Sandro Nuciforo Switzerland 13 366 1.0× 389 1.7× 236 1.8× 307 2.5× 46 0.4× 17 1.0k
Dongmei Fan China 16 361 1.0× 321 1.4× 66 0.5× 60 0.5× 35 0.3× 54 751
Natalia Bednarz‐Knoll Poland 16 481 1.3× 280 1.2× 344 2.6× 117 0.9× 45 0.4× 28 800
Takehiro Nohara Japan 11 389 1.1× 351 1.5× 156 1.2× 41 0.3× 48 0.4× 25 784
Antonio Daponte Italy 15 529 1.5× 315 1.4× 128 1.0× 84 0.7× 179 1.5× 37 843
Eugenia R. Zanella Italy 7 399 1.1× 313 1.4× 213 1.6× 49 0.4× 38 0.3× 14 668

Countries citing papers authored by Clinton Yam

Since Specialization
Citations

This map shows the geographic impact of Clinton Yam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clinton Yam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clinton Yam more than expected).

Fields of papers citing papers by Clinton Yam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clinton Yam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clinton Yam. The network helps show where Clinton Yam may publish in the future.

Co-authorship network of co-authors of Clinton Yam

This figure shows the co-authorship network connecting the top 25 collaborators of Clinton Yam. A scholar is included among the top collaborators of Clinton Yam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clinton Yam. Clinton Yam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yam, Clinton, et al.. (2026). Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 394(4). 354–366. 1 indexed citations
2.
Wu, Chengyue, Ernesto A. B. F. Lima, Zhan Xu, et al.. (2025). MRI-based digital twins to improve treatment response of breast cancer by optimizing neoadjuvant chemotherapy regimens. npj Digital Medicine. 8(1). 195–195. 7 indexed citations
3.
Wu, Chengyue, David A. Hormuth, Jingfei Ma, et al.. (2025). Personalizing neoadjuvant chemotherapy regimens for triple-negative breast cancer using a biology-based digital twin. npj Systems Biology and Applications. 11(1). 53–53. 2 indexed citations
4.
Garber, Haven R., Sreyashi Basu, Sonali Jindal, et al.. (2024). Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer. Oncotarget. 15(1). 238–247. 2 indexed citations
5.
Kalinsky, Kevin, Laura M. Spring, Clinton Yam, et al.. (2024). Real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line and later-line treatment of metastatic triple-negative breast cancer in the United States. Breast Cancer Research and Treatment. 208(1). 203–214. 6 indexed citations
6.
Wu, Chengyue, Zhan Xu, Clinton Yam, et al.. (2024). Combining Biology-based and MRI Data-driven Modeling to Predict Response to Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Radiology Artificial Intelligence. 7(1). e240124–e240124. 3 indexed citations
7.
Wang, Jing, Hongxia Sun, Phyu P. Aung, et al.. (2023). TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Archives of Pathology & Laboratory Medicine. 148(2). 200–205. 9 indexed citations
8.
Yam, Clinton, Mediget Teshome, Henry M. Kuerer, et al.. (2023). Axillary Nodal Metastases Conversion and Perioperative Complications with Neoadjuvant Pembrolizumab Therapy in Triple-Negative Breast Cancer. Annals of Surgical Oncology. 31(2). 974–980. 4 indexed citations
9.
Kasi, Pashtoon Murtaza, Nava Almog, Clinton Yam, et al.. (2023). RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.. Journal of Clinical Oncology. 41(16_suppl). e15058–e15058. 1 indexed citations
10.
11.
Kalinsky, Kevin, Laura M. Spring, Clinton Yam, et al.. (2023). Real-world outcomes in patients (pts) with metastatic triple-negative breast cancer (mTNBC) treated with sacituzumab govitecan (SG) in 2L+ in the United States (US).. Journal of Clinical Oncology. 41(16_suppl). e18879–e18879. 2 indexed citations
12.
Wu, Chengyue, Angela M. Jarrett, Zijian Zhou, et al.. (2022). MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer. Cancer Research. 82(18). 3394–3404. 45 indexed citations
13.
Sun, Xiangjie, Jie Zhai, Baohua Sun, et al.. (2021). Effector memory cytotoxic CD3+/CD8+/CD45RO+ T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer. Modern Pathology. 35(5). 601–608. 23 indexed citations
14.
Yam, Clinton, Gaiane M. Rauch, Meghan Karuturi, et al.. (2020). A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Investigational New Drugs. 39(2). 509–515. 24 indexed citations
15.
16.
Yam, Clinton, Rashmi K. Murthy, Vicente Valero, et al.. (2018). A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Investigational New Drugs. 36(2). 299–306. 18 indexed citations
17.
Goldberg, David S., Amol Agarwal, K. Gene, et al.. (2017). Endoscopic Therapy is Effective for Recurrent Anastomotic Biliary Strictures after Orthotopic Liver Transplantation. Annals of Hepatology. 16(6). 924–931. 7 indexed citations
18.
Yam, Clinton, Sendurai A. Mani, & Stacy L. Moulder. (2017). Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field. The Oncologist. 22(9). 1086–1093. 74 indexed citations
19.
Yam, Clinton, Kenneth R. Hess, Jennifer K. Litton, et al.. (2017). A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS).. Journal of Clinical Oncology. 35(15_suppl). TPS590–TPS590. 4 indexed citations
20.
Yam, Clinton, Ming Zhao, Katsuhiro Hayashi, et al.. (2009). Monotherapy with a Tumor-Targeting Mutant of S. typhimurium Inhibits Liver Metastasis in a Mouse Model of Pancreatic Cancer. Journal of Surgical Research. 164(2). 248–255. 120 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yunxin Lai Breakdown of academic impact, for papers by Joris van de Haar Breakdown of academic impact, for papers by Matthew A. Spear Breakdown of academic impact, for papers by Shuguang Zuo Breakdown of academic impact, for papers by Sandro Nuciforo Breakdown of academic impact, for papers by Dongmei Fan Breakdown of academic impact, for papers by Natalia Bednarz‐Knoll Breakdown of academic impact, for papers by Takehiro Nohara Breakdown of academic impact, for papers by Antonio Daponte Breakdown of academic impact, for papers by Eugenia R. Zanella
Rankless by CCL
2026